Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Chronic hyperglycemia impairs insulin action, resulting in glucotoxicity, which can be ameliorated in animal models by inducing glucosuria with renal glucose transport inhibitors. Here, we examined whether reduction of plasma glucose with a sodium-glucose cotransporter 2 (SGLT2) inhibitor could improve insulin-mediated tissue glucose disposal in patients with type 2 diabetes. Eighteen diabetic men were randomized to receive either dapagliflozin (n = 12) or placebo (n = 6) for 2 weeks. We measured insulin-mediated whole body glucose uptake and endogenous glucose production (EGP) at baseline and 2 weeks after treatment using the euglycemic hyperinsulinemic clamp technique. Dapagliflozin treatment induced glucosuria and markedly lowered fasting plasma glucose. Insulin-mediated tissue glucose disposal increased by approximately 18% after 2 weeks of dapagliflozin treatment, while placebo-treated subjects had no change in insulin sensitivity. Surprisingly, following dapagliflozin treatment, EGP increased substantially and was accompanied by an increase in fasting plasma glucagon concentration. Together, our data indicate that reduction of plasma glucose with an agent that works specifically on the kidney to induce glucosuria improves muscle insulin sensitivity. However, glucosuria induction following SGLT2 inhibition is associated with a paradoxical increase in EGP. These results provide support for the glucotoxicity hypothesis, which suggests that chronic hyperglycemia impairs insulin action in individuals with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Long-term effects of sodium-glucose transport protein 2 inhibitors (SGLT2i) might enhance insulin sensitivity, thereby mitigating muscle catabolism and influencing the quality and functionality of the skeletal muscle.30,31”
From Imaging of Sarcopenia in Type 2 Diabetes Mellitus (2024) · cites this paper as [31]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425 · cited 2×
“After the start of insulin, no glucose was infused until the plasma glucose concentration declined to 100 mg/dl, at which level it was maintained by the adjustment of a variable glucose infusion based on the negative feedback principle (27).”
Self-citationDeFronzo, R. A., Jacot, E., Jequier, E., Maeder, E., Wahren, J., & Felber, J. P. (1981) · Diabetes · doi:10.2337/diab.30.12.1000 · Cited by 1,770 · cited 1×
“Since >80% of insulin-mediated glucose disposal during the euglycemic insulin clamp takes place in skeletal muscle (16), these results indicate that lowering the plasma glucose concentration in T2DM significantly improves muscle insulin resistance and are consistent with a glucotoxic effect of chronic hyperglycemia to…”
Self-citationMeasurement of Size and Turnover Rate of Body Glucose Pool by the Isotope Dilution Method
Steele, R., Wall, J. S., de Bodo, R. C., & Altszuler, N. (1956) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1956.187.1.15 · Cited by 816 · cited 1×
“After drug administration and during the insulin clamp, nonsteady-state conditions for 3-3 H-glucose–specific activity prevail and the rate of glucose appearance ( R a ) was calculated with Steele’s equation (28).”
Groop, L. C., Bonadonna, R. C., DelPrato, S., Ratheiser, K., Zyck, K., Ferrannini, E., & DeFronzo, R. A. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114142 · Cited by 812 · cited 1×
“However, these latter studies are difficult to interpret, since insulin therapy also exerts other metabolic effects, e.g., reduction in plasma free fatty acid concentration (12), which profoundly affect insulin sensitivity independent of changes in plasma glucose concentration (13).”
Self-citationRossetti, L., Smith, D., Shulman, G. I., Papachristou, D., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 809
Self-citationRossetti, L., Giaccari, A., & DeFronzo, R. A. (1990) · Diabetes Care · doi:10.2337/diacare.13.6.610 · Cited by 770
Self-citationDeFronzo, R. A., Ferrannini, E., & Simonson, D. C. (1989) · Metabolism · doi:10.1016/0026-0495(89)90129-7 · Cited by 515 · cited 1×
“Because of the close relationship between EGP (primarily reflects liver) and the fasting plasma glucose concentration (17), the decrease in FPG brought about by dapagliflozin would be expected to be associated with a decrease in HGP.”
Self-citationBanting Lecture 1997. Control of glucose uptake and release by the liver in vivo.
Cherrington, A. D. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1198 · Cited by 502
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Abdul-Ghani, M. A., Norton, L., & DeFronzo, R. A. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0029 · Cited by 443 · cited 1×
“…the impact of chronic hyperglycemia on insulin sensitivity in individuals with T2DM, we examined the effect of lowering the plasma glucose concentration on whole body insulin sensitivity by inhibiting renal sodium-glucose cotransport with dapagliflozin (15) using the insulin clamp technique.”
Self-citationDose-Response Effect of Elevated Plasma Free Fatty Acid on Insulin Signaling
Belfort, R., Mandarino, L., Kashyap, S., Wirfel, K., Pratipanawatr, T., Berria, R., DeFronzo, R. A., & Cusi, K. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1640 · Cited by 404 · cited 1×
“However, these latter studies are difficult to interpret, since insulin therapy also exerts other metabolic effects, e.g., reduction in plasma free fatty acid concentration (12), which profoundly affect insulin sensitivity independent of changes in plasma glucose concentration (13).”
Self-citation
Research works printed but not linked: 1
- Del Prato S, Leonetti F, Simonson DC, Sheehan P, Matsuda M, DeFronzo RA. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia. 1994;37(10):1025-1035. · DOI · Paper page
Cited by
Items 301–400 of 789
Yanai, H., Katsuyama, H., Hamasaki, H., Adachi, H., Moriyama, S., Yoshikawa, R., & Sako, A. (2015) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2385w · Cited by 31
On behalf of the UTOPIA study investigators, Katakami, N., Mita, T., Yoshii, H., Shiraiwa, T., Yasuda, T., Okada, Y., Umayahara, Y., Kaneto, H., Osonoi, T., et al. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0292-1 · Cited by 32
Lundkvist, P., Pereira, M. J., Kamble, P. G., Katsogiannos, P., Langkilde, A. M., ESTERLINE, R. L., JOHNSSON, E. K., & Eriksson, J. W. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00969 · Cited by 33
Molecular signaling mechanisms of renal gluconeogenesis in nondiabetic and diabetic conditions
Swe, M. T., Pongchaidecha, A., Chatsudthipong, V., Chattipakorn, N., & Lungkaphin, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27598 · Cited by 37
Baker, C., Wason, S., Banks, P. L., Sawhney, S., Chang, A., Danne, T., Gesty‐Palmer, D., Kushner, J. A., McGuire, D. K., Mikell, F. L., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13825 · Cited by 30
Wolf, P. S., Fellinger, P., Pfleger, L., Beiglböck, H., Krumpolec, P., Barbieri, C., Gastaldelli, A., Harreiter, J., Metz, M., Scherer, T., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1983 · Cited by 32
Xie, L., & Wenfang, X. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120543 · Cited by 36
From an Apple to a Pear: Moving Fat around for Reversing Insulin Resistance
Alser, M., & Elrayess, M. A. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192114251 · Cited by 37
Dapagliflozin: Glucuretic action and beyond
Balakumar, P., Sundram, K., & Dhanaraj, S. A. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.03.008 · Cited by 31
Pereira, M. J., Lundkvist, P., Kamble, P. G., Lau, J., Martins, J. G., Sjöström, C. D., Schnecke, V., Walentinsson, A., JOHNSSON, E. K., & Eriksson, J. W. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0449-6 · Cited by 32
GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
Złotek, M., Kurowska, A., Herbet, M., & Piątkowska‐Chmiel, I. (2023) · Biomedicines · doi:10.3390/biomedicines11113035 · Cited by 32
“Exciting recent discoveries have unveiled the pivotal role of SGLT-2 inhibition in reshaping our understanding of insulin sensitivity in peripheral tissues, a breakthrough brought to light by the research efforts of Merovci et al., 2014 and Yaribeygi et al., 2020.”
BackgroundVaziri, Z., Saleki, K., Aram, C., Alijanizadeh, P., Pourahmad, R., Azadmehr, A., & Ziaei, N. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115686 · Cited by 31
Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions
Kalra, S., Gupta, Y., & Patil, S. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.152793 · Cited by 29
“[16] As SGLT‐2 inhibitor treatment is known to increase plasma FFA levels,[2,3] further research is warranted on effect of FFA on alpha cell with the use of SGLT‐2 Inhibitors.”
Triplitt, C. L., Solis‐Herrera, C., Cersósimo, E., Abdul‐Ghani, M. A., & DeFronzo, R. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1114098 · Cited by 33
Self-citationMETHOD DEVELOPMENT AND VALIDATION OF DAPAGLIFLOZIN IN API BY RP-HPLC AND UV-SPECTROSCOPY
Manasa, S., Dhanalakshmi, K., Nagarjuna Reddy, G., & Sreenivasa, S. (2014) · International Journal of Pharmaceutical Sciences and Drug Research · doi:10.25004/ijpsdr.2014.060317 · Cited by 29
Yoon, J., Min, S. H., Ahn, C. H., Cho, Y. M., & Hahn, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-22443-1 · Cited by 31
Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice
Qiao, P., Jia, Y., Ma, A., He, J., Shao, C., Li, X., Wang, S., Yang, B., & Zhou, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.934136 · Cited by 35
Shah, C. V., Hammad, N., Bhasin-Chhabra, B., & Rashidi, A. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2023.100697 · Cited by 30
Zhong, X., Lai, D., Ye, Y., Yang, X., Yu, B., & Huang, Y. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2010-8 · Cited by 34
“Second, SGLT2 inhibitor leads to a reduction in tissue glucose disposal and a rise in endogenous glucose production (EGP) [9, 10].”
BackgroundAbdul-Ghani, M. A., Jobori, H. A., Daniele, G., Adams, J. M., Cersósimo, E., Triplitt, C. L., & DeFronzo, R. A. (2017) · Diabetes · doi:10.2337/db17-0055 · Cited by 33
Self-citationRenal Tubular Handling of Glucose and Fructose in Health and Disease
Vallon, V., & Nakagawa, T. (2021) · Comprehensive physiology · doi:10.1002/cphy.c210030 · Cited by 54
Abdelgani, S., Khattab, A., Adams, J. M., Abu‐Farha, M., Daniele, G., Al‐Mulla, F., Prato, S. D., DeFronzo, R. A., & Abdul‐Ghani, M. A. (2023) · Diabetes Care · doi:10.2337/dc22-0885 · Cited by 29
Self-citationRroji, M., Spahia, N., Figurek, A., & Spasovski, G. B. (2025) · Biomedicines · doi:10.3390/biomedicines13030728 · Cited by 35
“Treatment with SGLT2 inhibitors was observed to modestly improve insulin sensitivity by ∼ 25% to 30% in diabetic animal experimental models [247] and clinical T2DM studies [248] within 2 weeks of treatment initiation.”
Thewjitcharoen, Y., Yenseung, N., Malidaeng, A., Nakasatien, S., Chotwanvirat, P., Krittiyawong, S., Wanothayaroj, E., & Himathongkam, T. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0297-y · Cited by 33
Handelsman, Y., Mathieu, C., Prato, S. D., JOHNSSON, E. K., Kurlyandskaya, R., Iqbal, N., García‐Sánchez, R., & Rosenstock, J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13594 · Cited by 27
Thongnak, L., Chatsudthipong, V., Kongkaew, A., & Lungkaphin, A. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.114997 · Cited by 29
SGLT2 inhibitors for genetic and acquired insulin resistance: Considerations for clinical use
Hosokawa, Y., & Ogawa, W. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13309 · Cited by 28
Lee, S., Min, K. W., Lee, B., Jeong, I., Yoo, S.-J., Kwon, H., Choi, Y., & Yoon, K. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0203 · Cited by 30
Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis
Gronda, E., Lopaschuk, G. D., Arduini, A., Santoro, A., Benincasa, G., Palazzuoli, A., Gabrielli, D., & Napoli, C. (2022) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2021-0399 · Cited by 31
The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors
Ito, M., & Tanaka, T. (2018) · Internal Medicine · doi:10.2169/internalmedicine.9842-17 · Cited by 31
Carretero‐Gómez, J., Arévalo‐Lorido, J. C., Gómez‐Huelgas, R., de Lucas, M. D. G., Polo, L. M., Aguilar, J. M. V., Ripoll, J. M. S., & Ena, J. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2018.09.001 · Cited by 30
Comprehensive treatment of diabetic endothelial dysfunction based on pathophysiological mechanism
Liu, Z., Lu, J., Sha, W., & Lei, T. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1509884 · Cited by 44
Cintra, R. M. R., Moura, F. A., de Carvalho, L. S. F., Barreto, J., Tambascia, M. A., Pecoits‐Filho, R., & Sposito, A. C. (2019) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.65.1.70 · Cited by 32
Kurozumi, A., Shishido, K., Yamashita, T., Sato, D., Uchida, S., Koyama, E., Tamaki, Y., Hayashi, T., Miyashita, H., Yokoyama, H., et al. (2024) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.12.056 · Cited by 29
On behalf of the PROTECT Study Investigators, Tanaka, A., Murohara, T., Taguchi, I., Eguchi, K., Suzuki, M., Kitakaze, M., Sato, Y., Ishizu, T., Higashi, Y., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0449-7 · Cited by 27
Ekholm, E., Hansen, L., JOHNSSON, E. K., Iqbal, N., Carlsson, B., Chen, H., & Hirshberg, B. (2016) · Endocrine Practice · doi:10.4158/ep161323.or · Cited by 27
The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes
Jaikumkao, K., Pongchaidecha, A., Chatsudthipong, V., Chattipakorn, S. C., Chattipakorn, N., & Lungkaphin, A. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.07.095 · Cited by 28
Kurinami, N., Sugiyama, S., Nishimura, H., Morita, A., Yoshida, A., Hieshima, K., MIYAMOTO, F., Kajiwara, K., Jinnouchi, K., Jinnouchi, T., et al. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0580-6 · Cited by 30
“Our previous study showed that a muscle/fat ratio provided a good surrogate indicator of insulin resistance as assessed by the hyperinsulinemic-euglycemic clamp [13].”
ナトリウム・グルコース共輸送体2(SGLT2)阻害薬カナグリフロジンは非糖尿病マウスの遅筋および速筋に異なる影響を及ぼす
Otsuka, H. (2023) · Institutional Repositories DataBase (IRDB) · Cited by 27
MIAT LncRNA: A multifunctional key player in non-oncological pathological conditions
Zeinelabdeen, Y. A., Abaza, T., Yasser, M. B., Elemam, N. M., & Youness, R. A. (2024) · Non-coding RNA Research · doi:10.1016/j.ncrna.2024.01.011 · Cited by 29
“It is a cluster of metabolic disorders characterized by chronic hyperglycemia stemming from defects in insulin secretion, insulin action, or both [226 – 228].”
BackgroundPrevention and Treatment of Type 2 Diabetes: A Pathophysiological-Based Approach
Samocha‐Bonet, D., Debs, S. R., & Greenfield, J. R. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.03.014 · Cited by 29
Linden, M. A., Ross, T. T., Beebe, D. A., Gorgoglione, M. F., Hamilton, K. L., Miller, B. F., Braun, B., & Esler, W. P. (2019) · Metabolism · doi:10.1016/j.metabol.2019.05.009 · Cited by 27
Horibe, K., Morino, K., Miyazawa, I., Tanaka‐Mizuno, S., Kondo, K., Sato, D., Ohashi, N., Ida, S., Yanagimachi, T., Yoshimura, M., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109781 · Cited by 35
Kalra, S., Ghosh, S. K., Aamir, A., Ahmed, M. T., Amin, M. F., Bajaj, S., Baruah, M., Bulugahapitiya, U., Das, A., Giri, M., et al. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.196029 · Cited by 31
Yoshida, A., Matsubayashi, Y., Nojima, T., Suganami, H., Abe, T., Ishizawa, M., Fujihara, K., Tanaka, S., Kaku, K., & Sone, H. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02254 · Cited by 31
Cardiovascular Risks and Benefits of Medications Used for Weight Loss
Bramante, C. T., Raatz, S. J., Bomberg, E. M., Bensignor, M. O., & Ryder, J. R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00883 · Cited by 27
Acid-base and electrolyte disorders associated with the use of antidiabetic drugs
Filippatos, T. D., Tzavella, E., Rizos, C. V., Elisaf, M., & Liamis, G. L. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1361400 · Cited by 33
Combined effect of canagliflozin and exercise training on high-fat diet-fed mice
Tanaka, K., Takahashi, H., Katagiri, S., Sasaki, K., Ohsugi, Y., Watanabe, K., Rasadul, I. M. D., Mine, K., Nagafuchi, S., Iwata, T., et al. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00401.2019 · Cited by 26
D’Marco, L., Morillo, V., Górriz, J. L., Suarez, M., Nava, M., Ortega, Á., Parra, H., Villasmil, N., Rojas, J., & Bermúdez, V. (2021) · Journal of Diabetes Research · doi:10.1155/2021/9032378 · Cited by 33
Boeder, S. C., Thomas, R. L., Le Roux, M. J., Giovannetti, E. R., Gregory, J. M., & Pettus, J. H. (2025) · Diabetes Care · doi:10.2337/dc24-0212 · Cited by 25
Muscelli, E., Astiarraga, B., Barsotti, E., Mari, A., Schliess, F., Nosek, L., Heise, T., Broedl, U. C., Woerle, H., & Ferrannini, E. (2015) · Diabetologia · doi:10.1007/s00125-015-3845-8 · Cited by 34
Insulin Resistance and Insulin Handling in Chronic Kidney Disease
Parvathareddy, V. P., Wu, J., & Thomas, S. S. (2023) · Comprehensive physiology · doi:10.1002/cphy.c220019 · Cited by 64
“Therefore, these individuals with type 2 diabetes who were examined displayed significantly improved insulin-stimulated tissue glucose disposal (51).”
Park, J., Seo, I., Shim, H., & Cho, H. (2019) · Journal of Pineal Research · doi:10.1111/jpi.12623 · Cited by 25
Hattori, S. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00533-3 · Cited by 25
A Variation on the Theme: SGLT2 Inhibition and Glucagon Secretion in Human Islets
Hodson, D. J., & Rorsman, P. (2020) · Diabetes · doi:10.2337/dbi19-0035 · Cited by 26
Han, K. A., Kim, Y. H., Kim, D. M., Lee, B., Chon, S., Sohn, T. S., Jeong, I., Hong, E., Son, J. W., Nah, J. J., et al. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0315 · Cited by 25
“…decrease than dapa-gliflozin 10 mg. Previous studies demonstrated that, lowering plasma glucose concentration through enhanced glucosuria, dapagliflozin significantly improved insulin sensitivity in skeletal muscles in patients with T2DM and ameliorated pancreatic β-cell glucose toxicity [28-30].”
BackgroundRole of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus
Solini, A. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0856-y · Cited by 28
Patoulias, D., Stavropoulos, K., Imprialos, K. P., Katsimardou, A., Kalogirou, M., Koutsampasopoulos, K., Zografou, I., Papadopoulos, C. E., Karagiannis, A. I., & Doumas, M. N. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107927 · Cited by 24
Lin, Y., Lin, C.-H., Huang, Y., Tai, A., Fu, S., Chen, S., & Lin, S. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109816 · Cited by 27
Yamada, K., Nakayama, H., Yoshinobu, S., Kawano, S., Tsuruta, M., Nohara, M., Hasuo, R., Akasu, S., Tokubuchi, I., Wada, N., et al. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12370 · Cited by 23
Argento, N. B., & Nakamura, K. (2015) · Endocrine Practice · doi:10.4158/ep151016.or · Cited by 23
Furuhashi, M., Matsumoto, M., Hiramitsu, S., Omori, A., Tanaka, M., Moniwa, N., Yoshida, H., Ishii, J., & Miura, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154482 · Cited by 23
Kum-Nji, J. S., Gosmanov, A. R., Steinberg, H. O., & Dagogo-Jack, S. E. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.11.004 · Cited by 23
Aguilar-Ballester, M., Hurtado-Genovés, G., Taberner-Cortés, A., Herrero-Cervera, A., Martínez‐Hervás, S., & Navarro, H. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020660 · Cited by 29
Hanke, J., Romejko, K., & Niemczyk, S. (2025) · Molecules · doi:10.3390/molecules30204125 · Cited by 35
“They suppress pro-inflammatory cytokines, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α ), and interleukin-1 β (IL-1 β ) [55,123,124].”
Liver or kidney: Who has the oar in the gluconeogenesis boat and when?
Sahoo, B., Srivastava, M., Katiyar, A., ECELBARGER, C. A., & Tiwari, S. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i7.1049 · Cited by 27
Luong, T. V., Pedersen, M. G. B., Abild, C. B., Lauritsen, K. M., Kjærulff, M. L. G., Møller, N., Gormsen, L. C., & Søndergaard, E. (2024) · Diabetes · doi:10.2337/db24-0162 · Cited by 25
Millar, P., Pathak, V., Moffett, R. C., Pathak, N., Bjourson, A. J., O’Kane, M., Flatt, P. R., & Gault, V. A. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.11.019 · Cited by 24
“Indeed, recent observations by Bonner and co-workers (2015) and others (Merovci et al., 2014; Zambrowicz et al., 2013) suggest that SGLT2 inhibition can directly increase circulating glucagon and trigger glucagon secretion from pancreatic alpha-cells by limiting alpha-cell glucose uptake and…”
Rahelić, D., Javor, E., Lucijanić, T., & Skelin, M. (2016) · Annals of Medicine · doi:10.1080/07853890.2016.1226514 · Cited by 26
Tsimihodimos, V., Filippatos, T. D., & Elisaf, M. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1258055 · Cited by 24
“This increased glucose production could offset the glycosuria-associated antidiabetic effect of these drugs [57-60].”
BackgroundGoto, R., Kamimura, K., Shinagawa‐Kobayashi, Y., Sakai, N., Nagoya, T., Niwa, Y., Ko, M., Ogawa, K., Inoue, R., Yokoo, T., et al. (2019) · FEBS Open Bio · doi:10.1002/2211-5463.12598 · Cited by 22
SGLT2 Inhibitors: Multifaceted Therapeutic Agents in Cardiometabolic and Renal Diseases
Checa-Ros, A., Okojie, O.-J., & D’Marco, L. (2025) · Metabolites · doi:10.3390/metabo15080536 · Cited by 30
“These drugs induce a unique fasting-like metabolic state characterized by the following: Enhanced Lipolysis : Increased glucagon/insulin ratio promotes adipose tissue lipolysis, elevating free fatty acid (FFA) availability [30,31].”
Kosugi, R., Nakatani, E., Okamoto, K., Aoshima, S., Arai, H., & Inoue, T. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej19-0013 · Cited by 22
“The acute reaction of glucagon secretion to SGLT2 inhibition was reported to be significantly eleva‐ ted, which in turn stimulates hepatic glucose production and ketogenesis [14, 15].”
Backgroundvan Raalte, D. H., & Bjornstad, P. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz228 · Cited by 24
Sikirić, P., Udovičić, M., Barišić, I., Balenović, D., Živanović-Posilović, G., Strinić, D., Uzun, S., Sikirić, S., Krezić, I., Žižek, H., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10112696 · Cited by 21
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care
Caturano, A., Galiero, R., Rocco, M. P., Tagliaferri, G., Piacevole, A., Nilo, D., Lorenzo, G. D., Sardu, C., Vetrano, E., Monda, M., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12092039 · Cited by 28
“The efficacy of these drugs decreases progressively as blood glucose concentration falls [25].”
BackgroundThe treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus
Munir, K. M., & Davis, S. N. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1084502 · Cited by 24
“Recently, it has been reported treatment with SGLT2 inhibitors in individuals with T2DM, while decreasing renal glucose reabsorption, also increase endogenous glucose output, likely mediated by increases in glucagon [65].”
BackgroundRenal Effects of Antisense-Mediated Inhibition of SGLT2
van Meer, L., Moerland, M., van Dongen, M., Goulouze, B., de Kam, M., Klaassen, E. S., Cohen, A. F., & Burggraaf, J. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.233809 · Cited by 23
“…and empagliflozin resulted in similar paradoxical findings of altered glucose homeostasis and increased C-peptide/insulin levels, probably compensating for an increased endogenous glucose production (Cefalu, 2014; Ferrannini et al., 2014; Merovci et al., 2014; Scheen and Paquot, 2014).”
McLarnon, S. R., Patel, B., Irsik, D. L., Sun, J., Ocasio, H., Crislip, G. R., Jin, C., Chen, J., Baban, B., Polichnowski, A. J., et al. (2018) · Clinical Science · doi:10.1042/cs20171630 · Cited by 22
Marjot, T., Green, C., Charlton, C. A., Cornfield, T., Hazlehurst, J., Moolla, A., White, S. J., Francis, J. M., Neubauer, S., Cobbold, J., et al. (2019) · JGH Open · doi:10.1002/jgh3.12274 · Cited by 22
Dapagliflozin-induced Late-onset Euglycemic Diabetic Ketoacidosis
Iqbal, I., Hamid, M., Khan, M. A. A., Kainat, A., & Tariq, S. (2019) · Cureus · doi:10.7759/cureus.6089 · Cited by 22
Hattori, Y. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09921-3 · Cited by 26
Garg, R., Sood, N., Bansal, O., & Hoskote, A. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-09073-2 · Cited by 28
“21 Another study showed an increase in endogenous glucose production with SGLT-2 inhibitor use, along with a decrease in glucose oxidation accompanied by an increase in lipid oxidation.”
Iuchi, H., Sakamoto, M., Matsutani, D., Suzuki, H., Kayama, Y., Takeda, N., Minamisawa, S., & Utsunomiya, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-12106-y · Cited by 21
Atageldiyeva, K. K., Fujita, Y., Yanagimachi, T., Mizumoto, K., Takeda, Y., Honjo, J., Takiyama, Y., Abiko, A., Makino, Y., & Haneda, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157672 · Cited by 21
Zurek, A. M., Yendapally, R., & Urteaga, E. M. (2017) · Diabetes Spectrum · doi:10.2337/ds16-0030 · Cited by 23
“This enhances the secretion of glucagon from the pancreatic α-cells, which is referred to as an indirect effect of SGLT2 inhibitors on glucagon (49,50).”
BackgroundSuzuki, D., Yamada, H., Yoshida, M., Funazaki, S., Amamoto, M., Morimoto, J., & Hara, K. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13240 · Cited by 20
The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure
Riggs, K. A., Ali, H., Taegtmeyer, H., & Gutierrez, A. (2015) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2015.0038 · Cited by 22
Grøndahl, M. F. G., Keating, D. J., Vilsbøll, T., & Knop, F. K. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0967-z · Cited by 23
Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes
Powell, D. R., Doree, D. D., Jeter-Jones, S. L., Ding, Z., Zambrowicz, B., & Sands, A. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s76342 · Cited by 20
Practical combination therapy based on pathophysiology of type 2 diabetes
LEVIN, P. A. (2016) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s109216 · Cited by 22
“glucagon concentrations and endogenous glucose production, which could limit efficacy.(108,109) However, preclinical studies”
SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study
Tamez-Pérez, H. E., Delgadillo-Esteban, E., Soni-Duque, D., Hernández-Coria, M. I., & Tamez-Peña, A. L. (2017) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/s40200-017-0308-4 · Cited by 19
Therapeutic efficacy of dapagliflozin on diabetic kidney disease in rats
Yang, H., Mei, Z., Chen, W., Pan, Y., Liu, L., Zhao, R., Ni, W., Wang, Y., & Fei, C. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109272 · Cited by 28
Zhang, L., Lin, H., Yang, X., Shi, J., Sheng, X., Wang, L., Li, T., Quan, H., Zhai, X., & Li, W. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115852 · Cited by 22
Clinical implication of SGLT2 inhibitors in type 2 diabetes
Kim, G. W., & Chung, S. H. (2014) · Archives of Pharmacal Research · doi:10.1007/s12272-014-0419-0 · Cited by 24
Jurczak, M. J., Saini, S., Ioja, S., Costa, D. K., Udeh, N., Zhao, X., Whaley, J. M., & Kibbey, R. G. (2018) · Islets · doi:10.1080/19382014.2018.1503027 · Cited by 19
Sodium glucose co-transporter-2 inhibitor: Benefits beyond glycemic control
Baruah, M., Makkar, B. M., Ghatnatti, V., & Mandal, K. (2019) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_160_17 · Cited by 21
Yuan, T., Liu, S., Dong, Y., Fu, Y., Tang, Y., & Zhao, W. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00600-9 · Cited by 21
Targeting beta-cell preservation in the management of type 2 diabetes
Boughton, C. K., Munro, N. M., & Whyte, M. (2017) · British Journal of Diabetes · doi:10.15277/bjd.2017.148 · Cited by 24
Владиславовна, Х. Ю., Tikhonova, N., Gudkov, K., Erofeeva, S. B. E., Holmes, V., Dayton, B. D., Davies, N. M., Boulton, D. W., & Tang, W. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.02.006 · Cited by 20
Metadata
- Authors
- Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., & DeFronzo, R. A.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- DeFronzo, Ralph A.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-01-27
- Volume
- 124
- Issue
- 2
- Pages
- 509-514
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3904617
- OpenAlex
- W2166613497
- Cited by
- 795
- References
- 28
- Citations by year
- 2026: 26 · 2025: 40 · 2024: 52 · 2023: 55 · 2022: 64 · 2021: 58 · 2020: 91 · 2019: 63 · 2018: 71 · 2017: 71 · 2016: 79 · 2015: 82 · 2014: 43
- FWCI
- 73.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- National Institutes of Health (UL1TR001120, 5R01DK240923, KL2TR001118)
- University of Texas Health Science Center at San Antonio
- National Institute of Diabetes and Digestive and Kidney Diseases (5R01DK240923, R01DK024092)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dapagliflozin, SGLT2 inhibitors, type 2 diabetes, skeletal muscle insulin sensitivity, endogenous glucose production, glycosuria, glucotoxicity, hyperglycemia, insulin-stimulated glucose disposal, glucagon, renal glucose transport
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Fasting, Glucagon, Glucose, Glucosides, Humans, Hyperglycemia, Insulin, Male, Metformin, Middle Aged, Muscles, Sulfonylurea Compounds, Time Factors, Glucose Clamp Technique, Sodium-Glucose Transporter 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.